Abstract 590P
Background
Colorectal cancer (CRC) CRC with peritoneal metastasis (PM) obtain poor prognosis. Peritoneal Cancer Index (PCI) is used to evaluate the PM extent and selection of Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). However, PCI score assessed before surgery is not precise.We have developed a novel AI framework of DeAF (Decoupling feature alignment and fusion) to aid the selection and predict completeness of CRS in PM.
Methods
185 CRC patients with PM recruited from four tertiary hospitals were enrolled. The internal patient cohort was subsequently stratified into training and validation cohorts, comprising 84 and 30 individuals, respectively. Deep learning was used to train the DeAF model of Simsam algorithms by contrast CT images and then cooperate with clinicopathological parameters to increase the performance. The performance was evaluated by accuracy, sensitivity, specificity, and AUC by ROC in the internal and external validation cohorts.
Results
The AI model demonstrated a robust ability to predict the completeness of CRS with AUC of 0.9 in internal validation cohort. The model can predict whether patients are suitable for CRS. It can differentiate patients who would benefit from CRS. The model also showed high predictive performance of CRS completeness in external validation cohorts with AUC values of 0.906, 0.960, and 0.933, respectively (rounded to three decimal places).
Conclusions
The novel DeAF framework can aid surgeons to select proper patients for CRS and predict the completeness of CRS. The model can change surgical decision-making and provide potential benefits for patients with PM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
479P - The candidate novel markers PIV and PILE score to predict survival outcomes and therapeutic response in patients with primary central nervous system lymphoma
Presenter: Ling Duan
Session: Poster session 16
Resources:
Abstract
480P - Clinical utility of ctDNA detection by NGS for diagnosis of CNS lymphoma
Presenter: Ana Jiménez-Ubieto
Session: Poster session 16
481P - Integrating GWAS and transcriptomics prioritizes drug targets for meningioma
Presenter: Wan-Zhe Liao
Session: Poster session 16
482P - The prognostic impact of CDKN2A/B heterozygous deletions in meningioma: Insights of a multicenter analysis
Presenter: Franziska Ippen
Session: Poster session 16
483P - The use of steroids associated with PD1/PDL-1 blockage in patients with brain metastasis: A systematic review and meta-analysis
Presenter: Francisco Cezar Moraes
Session: Poster session 16
484P - EGFR amplification is the potential driver gene that accelerates brain metastases in NSCLC patients
Presenter: Hainan Yang
Session: Poster session 16
485P - A spatio-temporal evolution mathematical model of glioma growth: The influence of cellular and nutrient interactions on the tumor microenvironment
Presenter: Kalysta Borges
Session: Poster session 16
486P - Effects of a BBB-penetrating oligonucleotide drug, RBD8088, in mouse models of human glioblastoma
Presenter: Julia Grönros
Session: Poster session 16
487P - 3D-bioprinted co-cultures of glioblastoma and mesenchymal cells indicate a role for perivascular niche cells in shaping the chemotactic tumour microenvironment
Presenter: Radosław Zagożdżon
Session: Poster session 16
488P - ITGA2 promotes glioma cell stemness and progression by activating the AKT pathway
Presenter: Lihui Wang
Session: Poster session 16